Maxim Maintains Buy On OncoSec Medical Following UCSF Medical Collaboration
Maxim Group analyst Jason Kolbert maintained a Buy rating on OncoSec Medical (OTC:ONCS) with a price target of $3.00, as the company announced a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability, and efficacy of the combination of KEYTRUDA (pembrolizumab), Merck’s anti- PD-1 therapy, and OncoSec’s ImmunoPulse (intratumoral IL-12) in metastatic melanoma.
Kolbert noted, “We see OncoSec’s clinical collaboration with UCSF as a critical and positive step in the development of IL-12 immunotherapy. This is yet another sign giving validation of the value of the cancer-immune therapy as part of an overall therapeutic regimen to treat cancer. As such, we are encouraged by other signs we see in a handful of companies that directly support and validate this approach, such as Agenus, Bavarian Nordic, Inovio, and Medivation–just to name a few. We now see OncoSec as moving into a leadership position.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 5.1% and a 42.5% success rate. Kolbert has a 44.2% average return when recommending ONCS, and is ranked #719 out of 3385 analysts.